There are few pieces of researches focused on mutations in m6A-related genes in prostate cancer, but in AML, mutations in m6A writers such as METTL3, METTL14 and WTAP can enhance progression of leukemia, conferring unfavorable survival outcomes [20–23]. The gene discussed is METTL3; the disease is acute myeloid leukemia.